Damian Esq - Vertex Pharmaceuticals Chief VP
VRTX34 Stock | BRL 510.51 1.69 0.33% |
Insider
Damian Esq is Chief VP of Vertex Pharmaceuticals Incorporated
Age | 47 |
Phone | 617 341 6100 |
Web | https://www.vrtx.com |
Vertex Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.1733 % which means that it generated a profit of $0.1733 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2767 %, meaning that it generated $0.2767 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 8 records | INSIDER Age | ||
Sierk Poetting | BIONTECH SE DRN | 50 | |
Sean Marett | BIONTECH SE DRN | 58 | |
Michael Boehler | BIONTECH SE DRN | N/A | |
James Ryan | BIONTECH SE DRN | N/A | |
Ozlem MD | BIONTECH SE DRN | 56 | |
Ryan Richardson | BIONTECH SE DRN | 44 | |
Jens Holstein | BIONTECH SE DRN | 60 | |
Sylke Maas | BIONTECH SE DRN | N/A |
Management Performance
Return On Equity | 0.28 | |||
Return On Asset | 0.17 |
Vertex Pharmaceuticals Leadership Team
Elected by the shareholders, the Vertex Pharmaceuticals' board of directors comprises two types of representatives: Vertex Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vertex. The board's role is to monitor Vertex Pharmaceuticals' management team and ensure that shareholders' interests are well served. Vertex Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vertex Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
William Young, Independent Director | ||
Reshma Kewalramani, President, Chief Executive Officer, Director | ||
Michael Parini, Executive Vice President Chief Legal and Administrative Officer | ||
Alan Garber, Independent Director | ||
Mike Tirozzi, SVP Officer | ||
Damian Esq, Chief VP | ||
Jeffrey MD, Ex Chairman | ||
MD FASN, Pres CEO | ||
Stuart BSc, Ex COO | ||
John Gray, Senior Vice President Genetic Therapies | ||
Margaret McGlynn, Independent Director | ||
Diana McKenzie, Independent Director | ||
Sangeeta Bhatia, Independent Director | ||
Terrence Kearney, Independent Director | ||
Nia Tatsis, Senior Vice President Chief Regulatory Officer | ||
Kristen Ambrose, Tax, Accounting | ||
Paul Silva, Senior Vice President Controller | ||
David Altshuler, Executive Vice President - Global Research, Chief Scientific Officer | ||
Amit Sachdev, Executive Vice President Chief Regulatory Officer and Chief of Staff to the CEO | ||
Charles Wagner, Chief Financial Officer, Executive Vice President | ||
Gerald Bruce, Executive Vice President Commercial Operations | ||
Ourania Tatsis, Ex Officer | ||
Bruce Sachs, Co-Lead Independent Director | ||
Susie Lisa, VP Relations | ||
Lloyd Carney, Independent Director | ||
Yuchun Lee, Independent Director | ||
Stuart Arbuckle, Executive Vice President Chief Commercial Officer | ||
Carmen Bozic, Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer | ||
Jeffrey Leiden, Executive Chairman of the Board |
Vertex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vertex Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.28 | |||
Return On Asset | 0.17 | |||
Profit Margin | 0.37 % | |||
Operating Margin | 0.49 % | |||
Current Valuation | 372.17 B | |||
Shares Outstanding | 1.03 B | |||
Price To Earning | 18.08 X | |||
Price To Book | 6.20 X | |||
Price To Sales | 49.16 X | |||
Revenue | 8.93 B |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Vertex Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Vertex Pharmaceuticals' short interest history, or implied volatility extrapolated from Vertex Pharmaceuticals options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade Vertex Stock refer to our How to Trade Vertex Stock guide.Note that the Vertex Pharmaceuticals information on this page should be used as a complementary analysis to other Vertex Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Vertex Stock analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Commodity Directory Find actively traded commodities issued by global exchanges |